News & Insights
All the latest News and Insights from OHE, plus an archive of our monthly email bulletin.
Latest Insights
Is the revised Congressional Budget Office model of new drug development fit for purpose?
As U.S. drug-pricing policy changes accelerate, policymakers need reliable ways to understand how reduced pharmaceutical revenues might affect R&D incentives, but the Congressional Budget Office’s (CBO) revised simulation model of new drug development remains too simplified and insufficiently validated to guide real-world decisions.
Around the World in HTA: Japan – An algorithmic approach to containing costs
Japan’s health technology assessment (HTA) system uses algorithmic drug pricing and cost-effectiveness analysis to manage rising healthcare costs while maintaining universal access and innovation.
Seven reflections on the UK EQ-5D-5L value set – and what comes next
The long-awaited UK EQ-5D-5L value set has been published, marking a key moment for health technology assessment. Its adoption by NICE is set to shape how health-related quality of life is valued, raising important questions for future HTA decisions.
Europe’s pharmaceutical policy choices – And what the United States stands to learn
A recent policy discussion on Capitol Hill hosted by We Work For Health examined the lessons the United States might draw from Europe’s experience with pharmaceutical pricing and innovation. As a participant, my key takeaways focused on understanding the trade-offs underpinning EU and UK drug pricing policy and the broader impact on innovation for both sides of the Atlantic.
Latest News
Atherosclerotic cardiovascular disease (ASCVD) costs the world $680 billion a year in healthcare – roughly the size of Sweden’s entire economy, new research finds
The research also provides detailed, country-level insights into the health and economic costs of ASCVD across the US, Canada, UK, Netherlands, France, Germany, Spain, Italy, and Japan.
OHE responds to the 2025 UK Budget
Commenting on the newly announced 2025 UK Budget, Professor Graham Cookson, Chief Executive of the Office of Health Economics, said: “The NHS’ long-term sustainability will only come…
New research reveals, in carers’ own words, the multidimensional burden of caring for leukemia patients
Today, the Acute Leukemia Advocates Network (ALAN) and the Office of Health Economics (OHE published a first-of-its-kind qualitative study of informal carers across 6 countries.
New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy
A new report published today by the Cell and Gene Therapy Catapult (CGT Catapult) and the Office of Health Economics (OHE) presents a new method of quantifying the economic impact of healthcare innovations, such as cell and gene therapies.
New OHE model estimates COVID-19 could be associated with costs of £7 billion a year in the UK, without annual autumn vaccinations
A newly released report commissioned by Moderna modelled a one-year scenario without annual COVID-19 autumn vaccinations.
OHE responds to the NHS Ten Year Plan
Professor Graham Cookson responds to the Ten Year Health Plan for England.
Latest Podcasts
Most Favored Nation pricing: what it means for policy, patients and pharma
US pharmaceutical prices are the highest in the world – President Trump’s Most Favoured Nation (MFN) policy is trying to change that. But what does MFN pricing mean in practice?
Welcome to A Dose of Economics
When demand for healthcare is growing but budgets are finite, the “how” and “why” of decision-making matters.
